Second Generation Cell and Gene-Based Therapies

Biological Advances, Clinical Outcomes and Strategies for Capitalisation

1st Edition - February 7, 2020
Editors: Alain Vertes, Nathan J. Dowden, Devyn Smith, Nasib Qureshi
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 1 2 0 3 4 - 7
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 1 2 0 3 3 - 0

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalisation serves as the only volume to the market to bridge basic… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalisation serves as the only volume to the market to bridge basic science, clinical therapy, technology development, and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines, is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths, which will ultimately facilitate clinical delivery of cutting edge curative products.The next waves of innovation are reviewed in depth for hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as for enabling technologies such as gene and genome editing. Additionally, deep dives in product fundamentals, history of science, pathobiology of diseases, scientific and technological bases, and financing and technology adoption constraints are taken to unravel what will shape the cytotherapy industry to the horizon 2025 and beyond. The outcome is not simply a scientific book, but a global perspective on the nascent field combining science, business, and strategic fundamentals.

PART 1 Science

1. Innovation S- Curves in Living Drugs Development and Their Commercialisation

2. Development and Deployment of Gene Therapies: An ADA- SCID Case Study

3. Therapeutic Potential of Cells of the Immune System

4. T Cell Engineering and the Rise of CAR- T Cell Therapies

5. Harnessing Natural Killer Cells’ Killing Function in Cancer

6. Pluripotent Stem Cell–Derived Islet Replacement Therapy for Diabetes

7. Harnessing in Silico Technologies to Develop and Augment Second- Generation Cell- Based Therapies

8. Second Generation Genome Editing Technologies in Drug Discovery

9. The Next Wave: Tissue Replacement and Organ Replacement

10. Combining Stem Cells and Materials for Nerve Tissue Regeneration

PART 2 Translation

11. Gene Therapy Clinical Trials: Past, Present and Future

12. CAR-T Cell Clinical Trials Experience – Past, Present and Future

13. T Cell Receptor Engineered T Cell Therapy in Oncology

14. Cytotherapy Clinical Trials in Genetic Disorders of the Blood and Options for Reimbursement

PART 3 The Next Frontier

15.Mesenchymal Stromal Cell Therapies – The Next Frontiers

16. Regenerative Medicine and Ageing: Is Senescence Reprogrammable?

17. Deciphering the Systems Architecture of the Brain Using Molecular Can Openers

18. Harnessing the Therapeutic Potential of Dendritic Cells

19. Brief Overview of Chimeric Antigen Receptor–Mediated Immunotherapy for　Glioblastoma Multiforme

20. Combination Therapies in Solid Tumour Oncology

PART 4 Perspectives

21. Gene- Editing Technologies in Adoptive T Cell Therapy for Cancer: An Ethical Analysis

22. Decisions in the Development Lifecycle of Cell and Gene Therapies

23 CAR- T: From Concepts to Products – Now What?

24. Strategic Alliances in Cytotherapies and Gene Therapies: Funding the New Wave of Cell Therapeutics

25. The Role of Governments in the Commercial Emergence of Radical Innovation: The Case of the United Kingdom

26. Patenting Trends in Chimeric Antigen Receptor Technologies

27. Reimbursement and Payment Models for Therapies With Transformative and Curative Intent

28. Commercialising CAR- T Therapies: The Evolution of a Revolution

29. Will You Move the Needle of Medicine?

Alain Vertes

University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flanders-Artois

• Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois).

• Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.

• Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche).

• Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche’s global cell therapeutics strategy and implementation team resulting in Roche’s entry in 2010 in the field of regenerative medicine.

• Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society

• Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015).

Affiliations and expertise

NxR Biotechnologies GmbH, Basel, Switzerland

Nathan J. Dowden

Affiliations and expertise

Senior Vice President, Corporate Development, Rubius Therapeutics

Devyn Smith

• Head of Operations & Strategy, Medicinal Sciences Division of R&D, Pfizer Inc.

• Responsible for all cell & gene therapy products, as well as previously developing Pfizer’s Regenerative Medicine program.

• PhD in Genetics from Harvard Medical School.

• Adjunct faculty member at Northeastern University.

Affiliations and expertise

Head of Operations and Strategy, Medicinal Sciences Division of R&D, Pfizer Inc.

Nasib Qureshi

Research Chemical/Biochemical Engineer, United States Department of Agriculture (USDA), Agricultural Research Service (ARS), National Center for Agricultural Utilization Research (NCAUR), Peoria, IL, USA. PhD (Chemical/Biological Engineering), PhD (Fermentation Technology) Fellow in American Institute of Chemical Engineers (AIChE), Society for Industrial Microbiology & Biotechnology (SIMB), and American Institute of Chemists (AIC). Co-Editor, Stem cells in Regenerative Medicine (Wiley, 2015)

Affiliations and expertise

USDA-ARS-NCAUR, IL, USA. Affiliate Faculty, Institute for Genomic Biology, University of Illinois at Urbana-Champaign (UIUC), IL, USA (2004-2011). Adjunct Professor, UIUC (Biochemical Engineering, 2003-2018).